Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its earnings results on Thursday. The company reported $8.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $8.47, Zacks reports. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF traded up $0.88 during midday trading on Thursday, hitting $52.68. 180 shares of the stock were exchanged, compared to its average volume of 2,874. Zealand Pharma A/S has a twelve month low of $35.93 and a twelve month high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average price of $45.56 and a 200-day moving average price of $49.57. The stock has a market cap of $3.77 billion, a P/E ratio of 3.91 and a beta of 0.88.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Finally, Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, Zealand Pharma A/S has an average rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.